{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06253923",
            "orgStudyIdInfo": {
                "id": "MR-301-T-001"
            },
            "organization": {
                "fullName": "SHINKEI Therapeutics, Inc",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).",
            "officialTitle": "Multicenter, Double-blind, Randomized, Placebo Controlled, Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301), in Patients With Severe Traumatic Brain Injury (TBI).",
            "therapeuticArea": [
                "Other"
            ],
            "study": "study-to-assess-the-safety-of-amantadine-hydrochloride-hcl-intravenous-iv-solution-mr-in-patients-with-severe-traumatic-brain-injury-tbi"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-02",
            "studyFirstSubmitQcDate": "2024-02-09",
            "studyFirstPostDateStruct": {
                "date": "2024-02-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-28",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-01",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "SHINKEI Therapeutics, Inc",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Duke Clinical Research Institute",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main goal of this clinical trial is to check if the treatment is safe and well-tolerated. Researchers will compare the MR-301 active drug group with the placebo group to evaluate the safety and tolerability of the drug. Other measurements include assessing the patient's overall outcome, neurological responses, time spent in the intensive care unit, time in the hospital, and mortality. Participants will receive either MR-301 BID IV dosing or a matching placebo for a total of 3 weeks.",
            "detailedDescription": "This is a multi-center, randomized, placebo-controlled study of MR-301 administered BID IV in patients with severe TBI.\n\nParticipant: 45 patients with severe TBI who maintain GCS scores 3-8 both inclusive.\n\nIntervention: Mr-301 or placebo will be administered intravenously BID for upto 3 weeks.\n\nPrimary Outcome: Safety and Tolerability of MR-301\n\nSecondary Outcome: GOS-E, CRS-R, DRS, FOUR score, time to ICU discharge, time to hospital discharge and mortality."
        },
        "conditionsModule": {
            "conditions": [
                "Traumatic Brain Injury"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 45,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "MR-301",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "On first day, patient will receive MR-301 at 100 mg intravenous infusion BID. On second day, the dose is elevated to 150 mg intravenous infusion BID.\n\nOn third day, the dose is further elevated to 200 mg intravenous infusion BID and maintained up to Day 21",
                    "interventionNames": [
                        "Drug: Amantadine Hydrochloride"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Amantadine Hydrochloride",
                    "description": "MR-301 is an I.V. formulation for the treatment of TBI. The active ingredient is amantadine hydrochloride (HCl).",
                    "armGroupLabels": [
                        "MR-301"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "The placebo for this study is 0.9% Sodium Chloride IV Solution.",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Frequency, severity, and type of adverse events and serious adverse events between active treatment and placebo groups",
                    "description": "Safety and tolerability will be compared between active treatment and placebo groups.",
                    "timeFrame": "Day 1 to Day 35"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change from baseline in Glasgow Outcome Scale-Extended",
                    "timeFrame": "Day 21 and Day 35"
                },
                {
                    "measure": "Change from baseline in Disability Rating Scale (DRS) scale",
                    "timeFrame": "Day 5, Day 10, Day 15, Day 21"
                },
                {
                    "measure": "Change from baseline in Coma Recovery Scale - Revised",
                    "timeFrame": "Day 5, Day 10, Day 15, Day 21"
                },
                {
                    "measure": "Change from baseline in Full Outline of UnResponsiveness (FOUR) score",
                    "timeFrame": "every day up to Day 21"
                },
                {
                    "measure": "Time to intensive care unit (ICU) discharge to hospital floor",
                    "timeFrame": "up to day 21"
                },
                {
                    "measure": "Time to hospital discharge from randomization",
                    "timeFrame": "up to day 21"
                },
                {
                    "measure": "Mortality assessment at end of treatment period",
                    "timeFrame": "Day 21"
                },
                {
                    "measure": "Mortality assessment at end of study period (Day 35).",
                    "timeFrame": "Day 35"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age: 18 to 65 years.\n2. Patients with TBI confirmed by CT scan or MRI\n3. Patient have sustained a trauma between 72 hours to 1 week\n4. Patient with Abbreviated Injury Score (AIS) \u2264 2.\n5. Patients must be admitted to an acute care setting no less than 2 days prior to randomization.\n6. Glasgow Coma Score of 3 to 8, inclusive.\n7. Patients must be unable to consistently follow commands or to engage in functional communication, as assessed by the score on the CRS-R.\n8. Patients have at least one reactive pupil.\n9. Must have a Legally Authorized Representative (LAR) able to provide consent for the trial.\n10. Patient must have stable vitals ---Intracranial pressure ICP Value is at discretion of investigator), systolic blood pressure (SBP\\>90 mmHg) partial pressure of oxygen (PaO2 \\> 60 mmHg)\\].\n\nExclusion Criteria:\n\n1. Life expectancy of less than 24 hours.\n2. Patient has any spinal cord injury.\n3. Patient has a penetrating head injury.\n4. Patient has bilaterally fixed dilated pupils\n5. Patients with history of any medical or psychiatric disorder, or any severe concomitant disease that would, in the opinion of the Investigator, interfere with clinical assessment.\n6. Patient has poorly controlled seizure more than one per month.\n7. Prior history of status epilepticus\n8. Prior treatment with or a sensitivity to amantadine HCl or amantadine.\n9. Patient has screening lab measurements outside the normal range\n\n   1. Absolute neutrophil count (ANC): \u2264 1.5 x 109/L\n   2. Hemoglobin \u2264 8 g/dL or active bleeding requiring ongoing transfusions.\n   3. Platelets \u2264 80 x 109/L or active bleeding requiring ongoing transfusions.\n   4. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) or total bilirubin (unless isolated Gilbert's syndrome) \u2265 2x the upper limit of normal (ULN)\n   5. Estimated glomerular filtration rate (eGFR) \\< 60 ml/min/1.73m2\n10. Patient has received treatment with an investigational drug, CNS stimulant or dopamine antagonist/agonist within 4 weeks.\n11. Patient has a history of NYHA Class 3 or Class 4 Congestive Heart Failure within the last 5 years.\n12. Females who are nursing, pregnant, or planning to become pregnant\n13. any other clinically significant medical condition as determined by the Investigator, that may unfavorably alter the risk benefit of study participation.\n14. Patient has prolonged QT interval.\n15. Treatment with a systemic anticholinergic medication within 1 week prior to screening.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Adhiraj Dharmadhikari",
                    "role": "CONTACT",
                    "phone": "1 (609) 423-1570",
                    "email": "dharmadhikaria@shinkeitherapeutics.com"
                }
            ],
            "locations": [
                {
                    "facility": "Los Angeles General Medical Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90033",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Roy Poblete, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "UF Health Heart and Vascular Hospital",
                    "status": "RECRUITING",
                    "city": "Gainesville",
                    "state": "Florida",
                    "zip": "32608",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Thiago Carneiro, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.65163,
                        "lon": -82.32483
                    }
                },
                {
                    "facility": "Maine Medical Center",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Maine",
                    "zip": "04102",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Richard Riker, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.66147,
                        "lon": -70.25533
                    }
                },
                {
                    "facility": "Barnes Jewish Hospital",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Rajat Dhar, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "University of New Mexico Hospital",
                    "status": "RECRUITING",
                    "city": "Albuquerque",
                    "state": "New Mexico",
                    "zip": "87106",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Masoom Desai, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.08449,
                        "lon": -106.65114
                    }
                },
                {
                    "facility": "Department of Neurology, Duke University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27705",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Katharine Colton, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001930",
                    "term": "Brain Injuries"
                },
                {
                    "id": "D000070642",
                    "term": "Brain Injuries, Traumatic"
                },
                {
                    "id": "D000014947",
                    "term": "Wounds and Injuries"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000006259",
                    "term": "Craniocerebral Trauma"
                },
                {
                    "id": "D000020196",
                    "term": "Trauma, Nervous System"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5207",
                    "name": "Brain Injuries",
                    "asFound": "Brain Injury",
                    "relevance": "HIGH"
                },
                {
                    "id": "M628",
                    "name": "Brain Injuries, Traumatic",
                    "asFound": "Traumatic Brain Injury",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17685",
                    "name": "Wounds and Injuries",
                    "asFound": "Injury",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9349",
                    "name": "Craniocerebral Trauma",
                    "relevance": "LOW"
                },
                {
                    "id": "M22023",
                    "name": "Trauma, Nervous System",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC26",
                    "name": "Wounds and Injuries"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000547",
                    "term": "Amantadine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000978",
                    "term": "Antiparkinson Agents"
                },
                {
                    "id": "D000018726",
                    "term": "Anti-Dyskinesia Agents"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000015259",
                    "term": "Dopamine Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018712",
                    "term": "Analgesics, Non-Narcotic"
                },
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M3888",
                    "name": "Amantadine",
                    "asFound": "SOP",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4295",
                    "name": "Antiparkinson Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7473",
                    "name": "Dopamine",
                    "relevance": "LOW"
                },
                {
                    "id": "M17962",
                    "name": "Dopamine Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M20786",
                    "name": "Analgesics, Non-Narcotic",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "AnDyAg",
                    "name": "Anti-Dyskinesia Agents"
                },
                {
                    "abbrev": "CaAg",
                    "name": "Cardiotonic Agents"
                }
            ]
        }
    },
    "hasResults": false
}